首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Latest advances in biomarker discovery and development.
【24h】

Latest advances in biomarker discovery and development.

机译:生物标志物发现与发展的最新进展。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Oxford Global's 7th Annual Biomarkers Congress, held February 21-22, 2012, in Manchester (UK), gathered together approximately 300 delegates and speakers with a specific interest in biomarkers and their application in the field of drug discovery and development, as well as their enabling technologies. The audience and participants came from diverse and mixed backgrounds, from academicians and industry business professionals to representatives of solutions providers and CROs offering services in the field of biomarker assay development and sample analysis. Focus was broad, including all types of biomarkers and their application, i.e., prognostic and diagnostic markers, predictive markers, patient selection strategies in drug development, point-of-care solutions, pharmacodynamic and target engagement biomarkers as well as safety-related approaches. There were presentations spanning the entire range of biomarker development, from discovery to clinical qualification and analytical validation of a specific marker or a markers panel. A wide range of therapeutic areas were also covered; however, the fields of oncology and inflammatory diseases were more prominent, since they currently provide best case studies for biomarker discovery and clinical utility.
机译:2012年2月21日举行的牛津全球第7届年度生物标志物国会,在曼彻斯特(英国)举行,约300名代表和发言人,并对生物标志物的特定兴趣及其在药物发现和发展领域的应用以及他们的应用启用技术。观众和参与者来自多元化和混合的背景,来自院士和行业企业专业人员,以便在生物标志物测定开发和样本分析领域提供解决方案提供商和CROS提供服务的代表。焦点是广泛的,包括所有类型的生物标志物及其应用,即预后和诊断标志物,预测标志,药物开发中的患者选择策略,护理点溶液,药效动物和靶接合生物标志物以及与安全相关的方法。有介绍跨越整个生物标志物开发的演示,从发现到特定标记或标记面板的临床资格和分析验证。还覆盖了各种治疗区域;然而,肿瘤学和炎症性疾病的领域更加突出,因为他们目前为生物标志物发现和临床公用事业提供最佳案例研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号